rhHNS-10 mg
HGT-SAN-067
Phase 2 mab terminated
Quick answer
rhHNS-10 mg for Sanfilippo Syndrome is a Phase 2 program (mab) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Sanfilippo Syndrome
- Phase
- Phase 2
- Modality
- mab
- Status
- terminated